Market Cap (In USD)
9.92 Million
Revenue (In USD)
-
Net Income (In USD)
-8.4 Million
Avg. Volume
2232.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.023-0.09
- PE
- -0.3
- EPS
- -0.03
- Beta Value
- -2.226126
- ISIN
- GB00B0381Z20
- CUSIP
- -
- CIK
- -
- Shares
- 1102660000.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Richard Marsden
- Employee Count
- -
- Website
- https://www.synairgen.com
- Ipo Date
- 2020-07-20
- Details
- Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
More Stocks
-
BML-PGBank of America Corporation
BML-PG
-
PENG-B
-
002865
-
BCUR
-
7065UPR Corporation
7065
-
ALVERVergnet SA
ALVER
-
DELCFDelic Holdings Corp.
DELCF
-
HAR